Carteyva, JW Therapeutics, lymphoma, refractory follicular lymphoma, RELIANCE study, relmacabtagene autoleucel
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..
ADVL0912, anaplastic lymphoma kinase, lymphoma, NCT00939770, Pfizer, Xalkori
Crizotinib is approved by FDA for ALK-positive inflammatory myofibroblastic tumor
July 2022: Crizotinib (Xalkori, Pfizer Inc.) was granted approval by the Food and Drug Administration (FDA) for the treatment of adult and paediatric patients 1 year of age and older who were diagnosed with unresectable, recurr..
Carteyva, JW Therapeutics, Large B-cell lymphoma, lymphoma, NMPA, relmacabtagene autoleucel
JW Therapeutics’ IND is cleared by China NMPA for CAR T-Cell therapy in large B-Cell lymphoma
China's National Medical Products Administration (NMPA) has approved JW Therapeutics' investigational new drug (IND) application for a key clinical trial of Carteyva (relmacabtagene autoleucel) in people with second-line large B-c..
DLBCL, Hodgkin lymphoma, lymphoma, NHL, Non Hodgkin lymphoma
Why do young people have a high incidence of lymphoma?
LymphPeople have very little knowledge of lymph. The neck, groin, and armpits are all lymph. If there is a problem with the lymphatic system, the body's toxins will be stored in the body in large quantities, and lymphoma will soon..